Neurocrine Biosciences' Huntington's disease drug gets FDA approval [Reuters]
Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA)
Last teva pharmaceutical industries limited american depositary shares earnings: 2/13 04:01 pm
Check Earnings Report
US:NYSE Investor Relations:
ir.tevapharm.com
Company Research
Source: Reuters
treat movement disorders associated with Huntington's disease (HD), the company said on Tuesday. Huntington's disease is an inherited condition that causes the progressive breakdown of nerve cells in the brain, resulting in a gradual decline in motor control, cognition and mental stability. Ingrezza was first approved in 2017 in its oral capsule formulation to treat adults with movement disorders tardive dyskinesia and chorea. The granule formulation, Ingrezza Sprinkle, was developed as an alternative for patients with tardive dyskinesia and chorea who face difficulty swallowing capsules. The company did not immediately respond to a Reuters request seeking details on the drug's availability and pricing. Tardive dyskinesia is a medication-induced movement disorder characterized by uncontrollable movements of the face, torso and/or other body parts. Chorea associated with HD is a movement disorder that can interfere with swallowing and speech, among other bodily functions.
Show less
Read more
Impact Snapshot
Event Time:
TEVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TEVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TEVA alerts
High impacting Teva Pharmaceutical Industries Limited American Depositary Shares news events
Weekly update
A roundup of the hottest topics
TEVA
News
- Teva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global OperationsBusiness Wire
- Medincell Provides Update on Phase 3 mdc-CWM Clinical Trial [Yahoo! Finance]Yahoo! Finance
- Medincell to Host Videoconference on May 15, 2024, at 10:30 AM CEST to Discuss Company's Latest News, Outlook, and R&D Activities [Yahoo! Finance]Yahoo! Finance
- Teva Pharmaceutical Industries Limited (NYSE: TEVA) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $20.00 price target on the stock, up previously from $19.00.MarketBeat
- Teva Pharmaceutical Industries Limited (NYSE: TEVA) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.MarketBeat
TEVA
Earnings
- 5/8/24 - Miss
TEVA
Sec Filings
- 5/15/24 - Form 4
- 5/15/24 - Form 8-K
- 5/8/24 - Form 10-Q
- TEVA's page on the SEC website